WTAP and breast cancer: Levels of the m6A methylase “writers,” including METTL3, METTL14 and WTAP, were increased in brain, central nervous system (CNS), cervical, and head and neck cancer and sarcoma but decreased in BC, lymphoma and ovarian cancer as compared with normal controls.